Project Grant R37CA295609
Award Date
12/4/24
Completion Date
11/30/29
Dollars Obligated
$368K
Federal Agency
National Cancer Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Project Grant award of $730,398.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research aims to comprehensively characterize the lung cancer genomic landscape in patients of African ancestry. The key products and services to be delivered under this 5-year award include: Identifying and validating genomic differences between lung cancer patients of African and European ancestry, with a focus on drug targetable and...
This $932,740 Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund a study to determine racial disparities in lung cancer treatment and survival among Black and White non-small cell lung cancer (NSCLC) patients. The primary objectives are to: 1) document any racial differences in receipt of cancer treatments such as chemotherapy, immunotherapy, and combination therapies; 2) assess the impact...
This $334,233 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a research project conducted by the University of South Carolina to examine disparities in cancer care and outcomes. The project aims to: Describe and compare patterns of novel targeted therapies for lung and colon cancer by race, socioeconomic status, and urban/rural designation, and their impact on survival disparities. Describe and...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the immune response against a common mutation in lung cancer. The $216,460 award to Case Western Reserve University aims to fully characterize the immunogenic properties of the EGFR L858R mutation and evaluate the ability of EGFR L858R-specific T cells to suppress tumor growth. The research employs cutting-edge genetic and computational approaches...
This $432,304 federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a research project titled "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to enhance cancer risk prediction models, particularly for Black and Hispanic populations who face disproportionate cancer...
This $566,523 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support research to identify interception targets in persistent lung premalignant lesions (PMls) that are at high risk of progressing to lung cancer. The awardee, the University of Colorado-Denver, will use a reverse translational approach to: 1) identify interception targets in the persistence profile in clinical trial biopsies, 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at understanding the molecular mechanisms underlying the adeno-to-squamous transition observed in non-small cell lung cancer patients treated with KRAS inhibitors. The key objectives are to: Identify chromatin regulators that drive the adeno-to-squamous transition through a perturbation screen, and then...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $557,418 to The Trustees of Columbia University in the City of New York to conduct research aimed at targeting the SMARCA2 protein as a therapeutic approach for lung cancers with SMARCA4 deficiencies. The key research objectives are to: Assess the effects of SMARCA2 degradation on the progression of SMARCA4-deficient lung cancer using genetically engineered mouse models....
This Project Grant award of $158,365 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support research to understand the impact of NRF2 activation on lung squamous cell carcinoma (LUSC) initiation and progression. The award recipient, the University of North Carolina at Chapel Hill, will develop a novel genetically-engineered mouse model to assess how activated NRF2 affects LUSC incidence, tumor characteristics, gene expression, and the tumor...
This $2,372,456 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a multi-institutional research collaboration led by Memorial Sloan Kettering Cancer Center to leverage observational (real-world) data to advance precision oncology. The key products/services to be delivered include: Overcoming methodological barriers in analyzing observational clinico-genomic data (Project 1) Addressing the role of...